Harvard Bioscience (HBIO) Research & Development (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Research & Development data on file, last reported at $2.3 million in Q1 2026.

• Research & Development for Q1 2026 came in at $2.3 million, changed 0.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.8 million (down 10.28% YoY), and the FY2025 annual result was $8.8 million, down 15.19% from the prior year.
• Research & Development grew to $2.3 million in Q1 2026 per HBIO's latest filing, from $2.2 million in the prior quarter.
• Over five years, Research & Development peaked at $3.5 million in Q2 2022 and troughed at $2.1 million in Q3 2025.
• A 5-year average of $2.7 million and a median of $2.8 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2024: Research & Development increased 29.47% in 2022, then slipped 26.1% in 2024.
• A 5-year view of Research & Development shows it stood at $2.8 million in 2022, then gained by 10.57% to $3.2 million in 2023, then fell by 26.1% to $2.3 million in 2024, then decreased by 6.23% to $2.2 million in 2025, then rose by 6.55% to $2.3 million in 2026.
• Business Quant data shows HBIO's Research & Development at $2.3 million in Q1 2026, $2.2 million in Q4 2025, and $2.1 million in Q3 2025.